Patient health and well-being is why Cerus exists

At Cerus, blood safety is personal becasue protecting patients health and well-being is why we exists. Cerus passion to serve all patients requiring safe blood transfusions drives all of us to go the extra mile, to ensure that patients everywhere have access to safe blood in their time of need.

Proven in Routine Use

By reducing the risks of TTIs and certain undesirable adverse events, the INTERCEPT Blood System contributes to timely and safe blood transfusions while providing therapeutically effective products. INTERCEPT Plasma may be presribed and transfused in accordancewith the standard transfusion methods.

In Comparison to single-unit PI porcessing, the combination of the INTERCEPT Plasma Processing Set and the Plasma Pooling Set offers signicicant operational benefits.

Realise significant operational efficiencies at many steps of the transfusion chain

The INTERCEPT Blood System for plasma is flexible and adaptable. It allows a range of INTERCEPT Pathogen Inactivated Plasma Products to be manufactured from both apheresis and whole blood derived plasma. The process also allows more plasma to be available to the plasma fractionation industry to produce plasma derived medicinal products (PDMPs).

Pooling 5 whole blood plasma units can yield 6x 200 mL plasma units

In Comparison to single-unit PI porcessing, the combination of the INTERCEPT Plasma Processing Set and the Plasma Pooling Set offers signicicant operational benefits. In many cases, 5 whole blood plasma units are an ideal pool size to produce 2 pools of approximately 650mL using the Plasma Pooling Set. Treating these requires just 2 INTERCEPT Plasma Processing Sets and yields 6x 200mL plasma units. In contrast, 6 separate sets and treatments are needed to produce 6 PI plasma units from single-unit processes. This process enables an addtional plasma unit to become available for use in fractionation, while ensuring the maintenacne of fresh frozen plasma (FFP) supply to patients.